Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma Inc has significantly bolstered its clinical and financial standing through the completion of an $8 million financing and the progression of EB103 into the Phase II stage of its ongoing trial, establishing a solid foundation for future growth. The positive recommendation from an independent Data and Safety Monitoring Board to advance into Phase II positions the company for immediate opportunities as it begins to gather additional safety and efficacy data from broader patient cohorts. Furthermore, advancements in the EB104 dual CD19/CD22 program and the potential for strategic partnerships indicate a promising pathway for addressing B-cell malignancies and expanding into the immunology sector as 2025 approaches.

Bears say

Estrella Immunopharma's recent stock decline raises significant concerns regarding potential dilution for shareholders, as management has indicated that strategic priorities will be discussed in an upcoming meeting, which could imply shifts in partnership and pipeline strategies. The revisions to financial assumptions have led to a conservative target price adjustment, reflecting an overall negative outlook on the company's growth prospects. Furthermore, the lack of clarity regarding the future development of their EB103 program and the overall financial health raises additional uncertainties about the company’s ability to successfully navigate the competitive landscape of biopharmaceuticals.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.